About this Journal Submit a Manuscript Table of Contents
Advances in Pharmacological Sciences
Volume 2012 (2012), Article ID 846163, 8 pages
http://dx.doi.org/10.1155/2012/846163
Research Article

Trends in Ambulatory Prescribing of Antiplatelet Therapy among US Ischemic Stroke Patients: 2000–2007

1College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
2RTI Health Solutions, Research Triangle Park, Durham, NC 27709, USA
3Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
4Division of Health Services Management and Policy, College of Public Health, The Ohio State University, Columbus, OH 43210, USA
5Ann Arbor VA Healthcare System and Departments of Medicine and Neurology, The University of Michigan, Ann Arbor, MI 48109, USA
6Health Services Management and Policy, The Ohio State University, Columbus, OH 43210, USA
7Department of Clinical, Social and Administrative Sciences, University of Michigan, Ann Arbor, MI 48109, USA
8Clinical, Social and Administrative Sciences, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, MI 48109, USA

Received 15 June 2012; Accepted 30 October 2012

Academic Editor: Paola Patrignani

Copyright © 2012 Sudeep Karve et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. L. Roger, A. S. Go, D. M. Lloyd-Jones, et al., “Heart disease and stroke statistics—2011 update: a report from the American Heart Association,” Circulation, vol. 123, no. 4, pp. e18–e209, 2011. View at Publisher · View at Google Scholar
  2. K. Hardie, G. J. Hankey, K. Jamrozik, R. J. Broadhurst, and C. Anderson, “Ten-year risk of first recurrent stroke and disability after first-ever stroke in the perth community stroke study,” Stroke, vol. 35, no. 3, pp. 731–735, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Thom, N. Haase, and W. Rosamond, “American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee,” Etal Circulation, vol. 14113, no. 6, pp. e85–e151, 2006.
  4. K. S. Wong and H. Li, “Long-term mortality and recurrent stroke risk among Chinese stroke patients with predominant intracranial atherosclerosis,” Stroke, vol. 34, no. 10, pp. 2361–2366, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal, “Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition),” Chest, vol. 133, supplement 6, pp. 630S–669S, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. R. L. Sacco, R. Adams, G. Albers et al., “Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association council on stroke: co-sponsored by the council on cardiovascular radiology and intervention. The American Academy of Neurology affirms the value of this guideline,” Stroke, vol. 37, no. 2, pp. 577–617, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. G. J. Hankey and C. P. Warlow, “Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations,” The Lancet, vol. 354, no. 9188, pp. 1457–1463, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal, “Antithrombotic and thrombolytic therapy for ischemic stroke,” Chest, vol. 119, supplement 1, pp. 300S–320S, 2001. View at Scopus
  9. J. Biller, “Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy,” Journal of the Neurological Sciences, vol. 284, no. 1-2, pp. 1–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Howard, L. A. McClure, J. W. Krakauer, and C. S. Coffey, “Stroke and the statistics of the aspirin/clopidogrel secondary prevention trials,” Current Opinion in Neurology, vol. 20, no. 1, pp. 71–77, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. P. A. Wolf, G. P. Clagett, J. D. Easton et al., “Preventing ischemic stroke in patients with prior stroke and transient ischemic attack : a statement for healthcare professionals from the Stroke Council of the American Heart Association,” Stroke, vol. 30, no. 9, pp. 1991–1994, 1999. View at Scopus
  12. N. K. Hills and S. C. Johnston, “Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack,” Stroke, vol. 39, no. 4, pp. 1228–1232, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. G. W. Albers, “Choice of endpoints in antiplatelet trials. Which outcomes are most relevant to stroke patients?” Neurology, vol. 54, no. 5, pp. 1022–1028, 2000. View at Scopus
  14. N. E. Schwartz and G. W. Albers, “Use of antiplatelet agents to prevent stroke: What is the role for combinations of medications?” Current Neurology and Neuroscience Reports, vol. 8, no. 1, pp. 29–34, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Kumar, G. C. Fonarow, K. A. Eagle et al., “Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH registry,” Critical Pathways in Cardiology, vol. 8, no. 3, pp. 104–111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. L. B. Goldstein, A. J. Bonito, D. B. Matchar, P. W. Duncan, and G. P. Samsa, “US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke: medical therapy in patients with carotid artery stenosis,” Stroke, vol. 27, no. 9, pp. 1473–1478, 1996. View at Scopus
  17. L. B. Goldstein, A. J. Bonito, D. B. Matchar et al., “US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke: design, service availability, and common practices,” Stroke, vol. 26, no. 9, pp. 1607–1615, 1995. View at Scopus
  18. S. Yusuf, F. Zhao, S. R. Mehta, S. Chrolavicius, G. Tognoni, and K. K. Fox, “Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation,” New England Journal of Medicine, vol. 345, no. 7, pp. 494–502, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. S. R. Steinhubl, P. B. Berger, J. T. Mann III et al., “Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial,” Journal of the American Medical Association, vol. 288, no. 19, pp. 2411–2420, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. P. H. C. Diener, P. J. Bogousslavsky, P. L. M. Brass et al., “Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 364, no. 9431, pp. 331–337, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. National Center for Health Statistics, “National Ambulatory Medical Care Survey (NAMCS)-Micro-Data File Documentation,” ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/namcs_public_use_files/.
  22. National Center for Health Statistics, “National Hospital Ambulatory Medical Care Survey (NHAMCS)-Micro-Data File Documentation,” ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHAMCS/.
  23. C. L. Roumie, E. Mitchel, P. S. Gideon, C. Varas-Lorenzo, J. Castellsague, and M. R. Griffin, “Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data,” Pharmacoepidemiology and Drug Safety, vol. 17, no. 1, pp. 20–26, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. L. B. Goldstein, “Accuracy of ICD-9-CM coding for the identification of patients with acute ischemic stroke: effect of modifier codes,” Stroke, vol. 29, no. 8, pp. 1602–1604, 1998. View at Scopus
  25. D. L. Tirschwell and W. T. Longstreth, “Validating administrative data in stroke research,” Stroke, vol. 33, no. 10, pp. 2465–2470, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. D. M. Reker, A. K. Rosen, H. Hoenig et al., “The hazards of stroke case selection using administrative data,” Medical Care, vol. 40, no. 2, pp. 96–104, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Buresly, M. J. Eisenberg, X. Zhang, and L. Pilote, “Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction,” Archives of Internal Medicine, vol. 165, no. 7, pp. 784–789, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. S. Berger, D. L. Bhatt, C. P. Cannon et al., “The relative efficacy and safety of clopidogrel in women and men. A sex-specific collaborative meta-analysis,” Journal of the American College of Cardiology, vol. 54, no. 21, pp. 1935–1945, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Chen, “CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke,” The Lancet, vol. 349, no. 9066, pp. 1641–1649, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. International Stroke Trial Collaborative Group, “The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke,” The Lancet, vol. 349, no. 9065, pp. 1569–1581, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. T. A. Pearson, S. N. Blair, S. R. Daniels et al., “AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases,” Circulation, vol. 106, no. 3, pp. 388–391, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. H. C. Diener, L. Cunha, C. Forbes, J. Sivenius, P. Smets, and A. Lowenthal, “European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke,” Journal of the Neurological Sciences, vol. 143, no. 1-2, pp. 1–13, 1996. View at Publisher · View at Google Scholar · View at Scopus
  33. ESPRIT Study Group, P. H. Halkes, J. van Gijn, L. J. Kappelle, P. J. Koudstaal, and A. Algra, “Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial,” The Lancet, vol. 367, no. 9523, pp. 1665–1673, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Fang, M. H. Alderman, N. L. Keenan, and J. B. Croft, “Declining US stroke hospitalization since 1997: national hospital discharge survey, 1988–2004,” Neuroepidemiology, vol. 29, no. 3-4, pp. 243–249, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Fang and M. H. Alderman, “Trend of stroke hospitalization, United States, 1988–1997,” Stroke, vol. 32, no. 10, pp. 2221–2225, 2001. View at Scopus